City of Hope
$100,000 Irving Feintech Family Foundation Career Development Research Grant
Research Title:
Optimizing Adoptive Immunotherapy Using Anti-CD22 Chimeric Antigen Receptor Redirected T-C ells for Lymphoma
Most patients with lymphoma are not cured with conventional therapy. New treatment is urgently needed.
This study proposes a novel strategy of inserting two genes into a patient’s own immune T cells. One gene will enable these cells to recognize and kill lymphoma cells; the other will serve as a cell self-destruct mechanism that activates on demand to eliminate modified T cells.
Dr. Budde describes ways to generate these modified T cells and test the feasibility of using them in mice and then in a clinical trial. Dr. Budde believes that our treatment has the potential to cure lymphoma patients in the future.
Mentor: Stephen Forman, MD